
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc. reported significant financial growth, with Cell Processing revenue reaching $25.3 million, marking a 33% year-over-year increase, and total revenue for 3Q25 at $28.1 million, reflecting a 31% year-over-year growth, which surpassed projections. Additionally, the company achieved net income of $0.6 million, or $0.01 per share, against expectations of a loss, indicating improved profitability. Management anticipates a gross margin in the low-60% range for 2025, along with a reduction in net loss and expansion of adjusted EBITDA margin, enhancing the company's financial outlook.
Bears say
BioLife Solutions faces several challenges that contribute to a negative outlook, including the risk of lower-than-projected growth in its product offerings and potential difficulties in acquiring new customers. Revenue guidance for FY2025 has been revised downwards, with an $8 million reduction in expectations leading to anticipated revenues of $95.0-96.0 million, which reflects a decline in growth momentum at 27-29% year-over-year. Additionally, the company remains susceptible to fluctuations in sales within emerging markets, foreign exchange rates, and potential dilution risks, which could further impair its financial stability.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares